EUnetHTA Magazine Summer 2021 – now available
We are pleased to publish the EUnetHTA Magazine for Summer 2021, the last issue of Joint Action 3 (2016-2021). While the magazine is intended to publish on a quarterly basis, the changes we have all experienced over the past year and a half have, understandably, presented a challenge to generating articles while our ‘regular’ workflows […]
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of bamlanivimab alone and bamlanivimab plus etesevimab combination for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for […]
PTRCR19 – REGN-COV2 for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of REGN-COV2 for the treatment of confirmed COVID-19 in patients aged 12 years and older that do […]
EUnetHTA-EFPIA Meeting Summary Now Available
We are pleased to publish the summary from the EUnetHTA-EFPIA Technical Meeting, held online on 1st December, 2020. Please follow the link to download. EUnetHTA-EFPIA Technical Meeting Summary – Dec 2020
Patient group input requested for new Rapid Reviews on medicinal products for COVID-19.
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]
Minutes of EMA/EUnetHTA virtual meeting
We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]
EMA-EUnetHTA Bilateral Meeting July 2020 – minutes now available
We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]
RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – report now available
EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19” is now available. This is the second rapid review assessing health technologies for SARS-CoV-2. The objective of this assessment was to identify, assess and summarise evidence on […]
PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.
This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national […]
PTRCR15 – remdesivir for the treatment of COVID-19. First update, December 2020.
In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This is the first update on the pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. Following the original Rapid Collaborative Review – PTRCR15, published in September 2020, evidence gaps were identified, such as the […]
